Why Human Biospecimens Are Critical in Liquid Biopsy Research

Whole blood is the starting material for many blood-based liquid biopsy workflows. Depending on the collection tube and processing method, whole blood may be used to produce plasma, serum, buffy coat, peripheral blood mononuclear cells, or other cellular fractions. Collection-tube chemistry, fill volume, mixing, transport, temperature, and the interval before processing can influence the fractions recovered and the analytes measured. For example, cellular degradation or lysis can release genomic DNA and dilute a low-abundance cell-free DNA signal.

Plasma is commonly used to study cell-free DNA, circulating tumor DNA, circulating RNA, proteins, extracellular vesicles, metabolites, and other circulating analytes. It is produced from anticoagulated blood, generally through one or more centrifugation steps that remove cells and cellular debris. Plasma-processing protocols must be matched to the intended analyte; high-sensitivity nucleic-acid studies may require tightly controlled processing and additional centrifugation to reduce residual cellular contamination.

Serum is collected after blood is allowed to clot and is frequently used for protein biomarkers, antibodies, serology, and other biomarker studies. The clotting process changes the sample matrix and can release cellular material, so serum and plasma are not interchangeable for every liquid biopsy application. The selected matrix should be justified and validated for the target analyte and assay.

Peripheral blood mononuclear cells, or PBMCs, provide lymphocytes and monocytes, available fresh or cryopreserved, for immune profiling, flow cytometry, functional assays, cytokine analysis, cell culture, and molecular studies. PBMCs are not a cell-free liquid-biopsy matrix, but they can complement plasma or serum by helping researchers characterize systemic immune responses, treatment effects, and cellular biomarkers in the same study.

In some applications, biofluids collected near the disease site may provide more informative biomarkers than blood. Depending on the indication and research question, investigators may consider:

• Cerebrospinal fluid for central nervous system tumors and neurological biomarkers, where blood may contain very low concentrations of disease-associated analytes.
• Urine for urinary-tract and kidney disease research and for nucleic-acid, protein, extracellular-vesicle, and metabolite studies.
• Saliva for oral and head-and-neck research and for accessible nucleic-acid, protein, antibody, hormone, or microbial biomarkers.
• Ascites fluid for studying cancer-associated cells, proteins, nucleic acids, and immune components within the abdominal cavity.
• Pleural fluid for thoracic oncology, respiratory disease, and biomarker research near the lung and pleural space.
• Synovial fluid for inflammatory and musculoskeletal research involving cells, proteins, and other joint-associated biomarkers.

These matrices differ substantially in composition, collection procedure, available volume, and processing requirements. A protocol developed for blood should not be assumed to transfer directly to another biofluid.

The collection protocol establishes the starting condition of the sample. Important variables include the collection tube and anticoagulant or preservative, venipuncture and draw order, tube fill and mixing, collection procedure for nonblood fluids, transport conditions, time to processing, temperature, and relevant donor or patient characteristics. These variables should be defined prospectively when possible and recorded consistently enough to evaluate comparability across specimens.

Centrifugation speed, duration, temperature, and number of spins can affect residual cells, platelets, debris, and analyte recovery in plasma. Delayed separation can permit cell lysis and increase background genomic DNA. Processing can also affect protein stability, extracellular-vesicle recovery, cellular viability, and the abundance of other analytes. Aliquot size, stabilization methods, and the time between collection and freezing should therefore be selected for the planned downstream workflow.

Storage temperature, storage duration, container type, aliquot volume, temperature excursions, and repeated freeze-thaw cycles may influence analyte concentration or integrity. The degree of sensitivity varies by analyte and assay, so studies should define acceptable storage history rather than apply a single rule to every specimen. Aliquoting can reduce unnecessary freeze-thaw exposure when multiple analyses are planned.

Preanalytical variability includes differences introduced before the analytical measurement begins, from collection through processing, storage, and shipment. If disease and control groups are collected or handled differently, a study may mistake protocol effects for biological differences. Harmonized procedures, documented deviations, balanced study design, and fit-for-purpose acceptance criteria help reduce that risk.

Clinical annotation allows researchers to define cohorts, identify potential confounders, interpret biomarker findings, and test associations with disease or treatment. Useful fields may include:

• Disease indication and confirmed diagnosis
• Disease stage, grade, burden, or status when relevant
• Treatment status, treatment history, and timing relative to specimen collection
• Demographic characteristics and other study-specific donor criteria
• Pathology, molecular testing, imaging, or laboratory information where applicable
• Collection time point, including longitudinal relationships among specimens
• Preanalytical metadata such as tube type, processing interval, centrifugation, storage, and freeze-thaw history

Not every field is available for every archived specimen or collection program. Investigators should identify required and optional data elements before sourcing begins and decide how missing, inconsistent, or differently defined fields will be handled.

For studies involving matched specimens, consistent donor or case identifiers are important for linking plasma, serum, cellular fractions, tissue, and associated clinical information.

Liquid biopsy research often measures analytes at low abundance, making background contamination and loss of signal especially consequential. A processing delay or unsuitable tube can permit blood-cell lysis, increasing background genomic DNA and reducing the relative fraction of circulating tumor DNA. Poor preservation can alter nucleic acids, proteins, vesicles, cells, or metabolites. Inconsistent centrifugation can leave residual cellular material, while repeated freeze-thaw cycles may add further variability.

These effects can lower sensitivity, increase background signal, create inconsistent measurements, obscure real differences between groups, and contribute to false-negative or irreproducible findings. They can also force teams to repeat work, replace cohorts, revise protocols, or delay assay development. Specimen quality is therefore part of assay design and validation—not merely a procurement or logistics concern.

ABS Bio provides whole blood and blood-derived products, including plasma, serum, and PBMCs, as well as specialty biofluids from normal and disease-state donors. Available inventory and prospective collection programs can support liquid biopsy development, biomarker discovery, translational research, and other fit-for-purpose applications. Plasma capabilities include double-spun processing intended to minimize residual cellular contamination for sensitive cfDNA, ctDNA, RNA, miRNA, and extracellular-vesicle research.

Collection and processing protocols can be tailored to project requirements, including anticoagulant selection, centrifugation procedures, aliquot volumes, and processing timelines.

Depending on the specimen and collection program, de-identified clinical and demographic information may include diagnosis, disease characteristics, medical and treatment history, laboratory or molecular results, biomarker information, and clinical outcomes. Study teams can define which data elements are essential during feasibility planning.

When existing specimens do not meet the required indication, format, processing protocol, time point, or clinical criteria, ABS Bio can design prospective collection programs around study-specific inclusion and exclusion criteria. The collection plan can address tube type, processing window, centrifugation, aliquoting, temperature, shipping, and clinical-data requirements so that sourcing is aligned with the downstream assay.

ABS Bio sources specimens under applicable IRB-approved protocols, with appropriate informed consent and patient-confidentiality protections. Its quality framework includes documented processes for specimen handling and traceability. Project teams should confirm the protocol, permitted use, de-identification approach, quality documentation, and study-specific acceptance criteria for the specimens being considered.

Liquid biopsy projects rarely begin with a catalog number alone. ABS Bio works as an extension of the research team, helping translate the scientific question into practical specimen criteria and evaluating inventory and prospective sourcing options. Early discussion of the analyte, assay, patient population, controls, metadata, volumes, and timeline can help identify feasibility issues before collection begins.

Discuss your liquid biopsy study, target analytes, donor criteria, collection protocol, clinical annotation, sample volumes, and timeline with ABS Bio. The team can help evaluate available specimens and custom collection options and develop a fit-for-purpose biospecimen strategy.